Related Experiment Video

Updated: Jul 18, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

Checkpoint kinase 1 inhibitor + low-dose hydroxyurea efficiently kills BRAF inhibitor- and immune checkpoint

Zhen Zeng1, Hung Long Ngo1, Martina Proctor1

  • 1Mater Research Institute, The University of Queensland, Brisbane, Queensland, Australia.

Pigment Cell & Melanoma Research
|August 24, 2023
PubMed

Insights

Checkpoint kinase 1 (CHK1) inhibitor plus low-dose hydroxyurea (LDHU) effectively targets melanoma replication stress. This combination shows promise for treating resistant melanomas by promoting anti-tumour immunity.

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunology

Background:

  • Melanoma treatments like targeted therapies and immunotherapies face resistance, limiting patient options.
  • Replication stress is a common characteristic of melanomas.
  • Existing treatments often fail due to acquired resistance mechanisms.

Purpose of the Study:

  • To investigate the efficacy of combining a checkpoint kinase 1 (CHK1) inhibitor with low-dose hydroxyurea (LDHU) in melanoma.
  • To determine if this combination can overcome resistance to BRAF inhibitors (BRAFi) and immune checkpoint inhibitors (ICI).
  • To assess the impact of this combination on anti-tumour immune responses in vivo.

Main Methods:

  • Utilizing melanoma cell lines with acquired resistance to BRAFi and ICI.
  • Treating resistant and sensitive melanoma models with CHK1 inhibitor plus LDHU.
  • Evaluating tumour sensitivity and immune responses in vivo.

Main Results:

  • Melanoma cell lines resistant to BRAFi or ICI remained sensitive to CHK1 inhibitor + LDHU.
  • The sensitivity of resistant cell lines was comparable to that of parental tumours.
  • In vivo studies showed that both BRAFi-resistant and BRAFi-sensitive tumours mounted an identical immune response to the treatment.

Conclusions:

  • The combination of CHK1 inhibitor and LDHU is a potential therapeutic strategy for melanomas resistant to current treatments.
  • This combination effectively targets melanoma replication stress and enhances anti-tumour immunity.
  • CHK1 inhibitor + LDHU offers a viable alternative for patients with refractory melanoma.
Keywords:
CHK1 inhibitorimmune responsereplication stresstreatment resistance

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

416
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
556